Delayed
Nasdaq Stockholm
14:37:07 14/05/2024 BST
|
5-day change
|
1st Jan Change
|
6.08
SEK
|
-0.33%
|
|
-0.33%
|
+8.96%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,071
|
1,233
|
1,108
|
1,524
|
1,633
|
1,785
|
-
|
-
|
Enterprise Value (EV)
1 |
815.7
|
945.2
|
963.6
|
1,396
|
1,438
|
1,872
|
1,666
|
1,379
|
P/E ratio
|
-16.7
x
|
-2.77
x
|
-11.2
x
|
-7.1
x
|
-4.29
x
|
-6.42
x
|
8.92
x
|
6.69
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
13
x
|
30.3
x
|
28.7
x
|
67.4
x
|
28.3
x
|
25.3
x
|
3.49
x
|
2.74
x
|
EV / Revenue
|
9.88
x
|
23.2
x
|
25
x
|
61.8
x
|
25
x
|
26.6
x
|
3.26
x
|
2.12
x
|
EV / EBITDA
|
-12.3
x
|
-5.31
x
|
-9.34
x
|
-7.14
x
|
-4.48
x
|
-7.72
x
|
7.35
x
|
4.37
x
|
EV / FCF
|
-13
x
|
-4.87
x
|
-
|
-8.05
x
|
-5.16
x
|
-5.59
x
|
23.1
x
|
4.86
x
|
FCF Yield
|
-7.68%
|
-20.5%
|
-
|
-12.4%
|
-19.4%
|
-17.9%
|
4.32%
|
20.6%
|
Price to Book
|
4.26
x
|
1.96
x
|
2.1
x
|
3.01
x
|
2.66
x
|
6.29
x
|
3.57
x
|
2.16
x
|
Nbr of stocks (in thousands)
|
53,533
|
165,069
|
165,069
|
214,589
|
292,571
|
292,571
|
-
|
-
|
Reference price
2 |
20.00
|
7.470
|
6.710
|
7.100
|
5.580
|
6.100
|
6.100
|
6.100
|
Announcement Date
|
18/02/20
|
17/02/21
|
17/02/22
|
22/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
82.56
|
40.66
|
38.54
|
22.6
|
57.6
|
70.5
|
510.8
|
650.6
|
EBITDA
1 |
-66.47
|
-178
|
-103.2
|
-195.4
|
-321.2
|
-242.4
|
226.5
|
315.6
|
EBIT
1 |
-66.68
|
-178.4
|
-105.7
|
-198.1
|
-324.8
|
-244.1
|
223.6
|
312.3
|
Operating Margin
|
-80.76%
|
-438.73%
|
-274.19%
|
-876.55%
|
-563.89%
|
-346.27%
|
43.77%
|
48.01%
|
Earnings before Tax (EBT)
1 |
-61.42
|
-179.1
|
-104.5
|
-193.8
|
-326.8
|
-304.8
|
200.2
|
294
|
Net income
1 |
-61.42
|
-179.1
|
-104.5
|
-193.8
|
-326.9
|
-304.8
|
174.6
|
255.5
|
Net margin
|
-74.4%
|
-440.51%
|
-271.23%
|
-857.52%
|
-567.53%
|
-432.38%
|
34.18%
|
39.27%
|
EPS
2 |
-1.200
|
-2.700
|
-0.6000
|
-1.000
|
-1.300
|
-0.9500
|
0.6836
|
0.9114
|
Free Cash Flow
1 |
-62.64
|
-194.2
|
-
|
-173.5
|
-278.4
|
-335
|
72
|
284
|
FCF margin
|
-75.87%
|
-477.55%
|
-
|
-767.7%
|
-483.33%
|
-475.18%
|
14.1%
|
43.66%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
31.79%
|
89.99%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
41.24%
|
111.17%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18/02/20
|
17/02/21
|
17/02/22
|
22/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
3.511
|
-
|
5.023
|
5.1
|
5.7
|
6.8
|
5.9
|
12.2
|
32.6
|
12.1
|
9
|
10
|
10
|
EBITDA
1 |
-31.95
|
-
|
-34.31
|
-54.7
|
-77.5
|
-74
|
-79.4
|
-85.6
|
-82.2
|
-
|
-85
|
-85
|
-85
|
EBIT
1 |
-32.62
|
-
|
-34.98
|
-55.4
|
-78.2
|
-74.9
|
-80.3
|
-86.5
|
-83.1
|
-68.6
|
-85
|
-85
|
-85
|
Operating Margin
|
-929.08%
|
-
|
-696.42%
|
-1,086.27%
|
-1,371.93%
|
-1,101.47%
|
-1,361.02%
|
-709.02%
|
-254.91%
|
-566.94%
|
-944.44%
|
-850%
|
-850%
|
Earnings before Tax (EBT)
1 |
-32.06
|
-
|
-33.24
|
-53.9
|
-77.8
|
-74.9
|
-79.5
|
-86.2
|
-86.1
|
-75
|
-88.43
|
-94.29
|
-94.59
|
Net income
1 |
-32.06
|
-28.82
|
-33.24
|
-53.09
|
-77.8
|
-74.9
|
-79.5
|
-86.2
|
-86.3
|
-75
|
-88.43
|
-94.29
|
-94.59
|
Net margin
|
-913.07%
|
-
|
-661.84%
|
-1,040.98%
|
-1,364.91%
|
-1,101.47%
|
-1,347.46%
|
-706.56%
|
-264.72%
|
-619.83%
|
-982.61%
|
-942.87%
|
-945.85%
|
EPS
2 |
-0.2000
|
-0.2000
|
-0.2000
|
-0.3000
|
-0.4000
|
-0.3000
|
-0.3000
|
-0.3000
|
-0.3000
|
-0.3000
|
-0.3023
|
-0.3223
|
-0.3059
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
17/02/22
|
26/04/22
|
19/08/22
|
08/11/22
|
22/02/23
|
26/04/23
|
22/08/23
|
08/11/23
|
22/02/24
|
03/05/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
87.2
|
-
|
-
|
Net Cash position
1 |
255
|
288
|
144
|
128
|
195
|
-
|
119
|
406
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.3599
x
|
-
|
-
|
Free Cash Flow
1 |
-62.6
|
-194
|
-
|
-174
|
-278
|
-335
|
72
|
284
|
ROE (net income / shareholders' equity)
|
-26.5%
|
-41%
|
-18.1%
|
-37.5%
|
-62.2%
|
-65.8%
|
49.3%
|
38.5%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
4.700
|
3.810
|
3.190
|
2.360
|
2.100
|
0.9700
|
1.710
|
2.820
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.02
|
-
|
-
|
-
|
3.95
|
12.1
|
39
|
Capex / Sales
|
-
|
0.06%
|
-
|
-
|
-
|
5.6%
|
2.36%
|
5.99%
|
Announcement Date
|
18/02/20
|
17/02/21
|
17/02/22
|
22/02/23
|
22/02/24
|
-
|
-
|
-
|
Average target price
13.38
SEK Spread / Average Target +119.26% Consensus |
1st Jan change
|
Capi.
|
---|
| +8.96% | 165M | | +5.50% | 111B | | +11.01% | 105B | | -12.26% | 22.34B | | -3.11% | 21.93B | | -6.13% | 18.59B | | -36.52% | 18.12B | | -9.51% | 16.96B | | +2.91% | 13.7B | | +37.46% | 12.45B |
Bio Therapeutic Drugs
|